Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide ...

Starting today, consumers can get an online diagnosis, prescription services, and Zepbound vials delivered to straight their homes — all via Ro. This partnership reflects the pharmaceutical ...

Direct-to-consumer health-care startup Ro said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly. Ro will ...

Under the new agreement, Ro patients who are prescribed Zepbound will be able to get vials of the drug through its app. Previously, Lilly had only made these vials, which are priced lower than its ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss drug Zepbound through a new partnership with Eli Lilly. Ro directly ...